Justin Yehuda Garber

Clinical Senior Lecturer

University of Sydney

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Justin Yehuda Garber is a Clinical Senior Lecturer at The University of Sydney, Australia. His research primarily focuses on multiple sclerosis, with recent articles addressing cognitive remediation, disease-modifying treatments, and predictive factors in disease progression. He has contributed to significant studies regarding treatment efficacy and clinical practices related to multiple sclerosis management.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (19)

Vilija Jokubaitis

MONASH UNIVERSITY

AUSTRALIA

Justin Yehuda Garber

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

COMBAT-MS (group-based cognitive remediation and behavioural approaches to intervention in multiple sclerosis).

Correction: Estimation of Transition Probabilities from a Large Cohort (&gt; 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.

Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.

The clinical relevance of MOG antibody testing in cerebrospinal fluid

Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse

Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study

Estimation of Transition Probabilities from a Large Cohort (&gt; 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Collaborators (19)

Vilija Jokubaitis

Tobias Sejbaek

Finn Sellebjerg

Helle Hvilsted Nielsen

Snehal Shah

Mark Slee

Peter Vestergaard Rasmussen

Giovanna De Luca

Eduardo Aguera-Morales

Maria José Sá

Clare Fraser

Adriane Sinclair

francesco patti

Alessandra Lugaresi

Deepak Gill

Izanne Roos

Allan Kermode

Daniel Kreiter

William L Herring

Make your next move.

Correction: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.

Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.